<DOC>
	<DOC>NCT01127308</DOC>
	<brief_summary>This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.</brief_summary>
	<brief_title>A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male participants with Body Mass Index of 17.5 to 30.5 kg/m2 and a total body weight &gt;50 kg (110 lbs) Female participants. Participants enrolled in a previous radionucleotide study or who have received radiotherapy or exposed to significant radiation within 12 months prior to screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Absorption</keyword>
	<keyword>Distribution</keyword>
	<keyword>Metabolism</keyword>
	<keyword>and Excretion</keyword>
	<keyword>Mass Balance</keyword>
	<keyword>Metabolic Profile</keyword>
	<keyword>Radiolabel Study</keyword>
</DOC>